The Food and Drug Administration approved Pfizer’s RSV vaccine for older adults – just weeks after the agency gave the green light to the first RSV shot for use in the U.S. Global market for RSV vaccines could reach $17 billion by 2033.
The race to grab a piece of a fast-growing market for respiratory-disease vaccines intensified this week as the Food and Drug Administration on Wednesday approved Pfizer’s PFE, -0.01% Abrysvo, a respiratory syncytial virus vaccine for older adults.
RSV often causes only mild coldlike symptoms, but it can also lead to lung infections or pneumonia. Up to 160,000 older adults are hospitalized and up to 10,000 die each year due to RSV infection, according to the Centers for Disease Control and Prevention. Adults age 65 and older and those with chronic heart or lung disease or weakened immune systems are at highest risk, according to the CDC.
More competition is on the horizon, with Moderna MRNA, +0.21% expected to launch an RSV vaccine next year. In a clinical trial, Pfizer’s RSV vaccine for older adults was 67% effective against lower-respiratory-tract illness with at least two signs or symptoms and 86% effective against illness with at least three signs or symptoms. In February, an FDA advisory panel narrowly backed the shot, with some panelists raising concerns about Guillain-Barre syndrome, a rare neurological reaction.
Österreich Neuesten Nachrichten, Österreich Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Iraq's $17 billion road-rail project will bridge Asia and EuropeIraq unveils an ambitious transport project that will connect Asia to Europe and enhance regional cooperation and economic opportunities.
Weiterlesen »
This $17 BTS-Inspired Speaker Is Perfect for House Parties and Listening Parties AlikeBTS may be on hiatus right now, but fans are still finding ways to celebrate the group and enjoy their songs. Case in point: this fan-made BTS Bluetooth speaker, which is on sale right now for just…
Weiterlesen »
Vatican questions how priest moved $17 million meant for missionary work into investment fundPope Francis has asked aides to get to the bottom of how at least $17 million was transferred from the Vatican’s U.S.-based missionary fundraising coffers into an impact investing vehicle run by a priest. The story of what happened to the money and how is one that has vexed Vatican officials on both sides of the Atlantic for over two years, all the more because it appears the transfers were completely legal. But they have nevertheless prompted the new leadership of the Vatican’s missionary fundraising operation in the U.S., The Pontifical Mission Societies, to fire the staff and board of directors who approved them, and overhaul its bylaws and statutes, to make sure nothing like this ever happens again.
Weiterlesen »
Pfizer gets FDA approval for RSV vaccine Abrysvo in older adultsPfizer Inc. said late Wednesday that the Food and Drug Administration approved its respiratory syncytial virus vaccine Abrysvo for older adults. The drug...
Weiterlesen »
FDA approves Pfizer RSV vaccine for older adultsThe approval of a vaccine by Pfizer targeting RSV comes just weeks after the Food and Drug Administration cleared a similar shot made by GSK.
Weiterlesen »
FDA approves Pfizer’s RSV vaccine for older adults | CNNThe US Food and Drug Administration on Wednesday approved Pfizer’s RSV vaccine for older adults, the second such shot approved for the common virus.
Weiterlesen »